Cancer Stem Cell News Volume 11.02 | Jan 12 2022

    0
    4







    2022-01-19 | CSCN 11.02


    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 11.02 – 19 January, 2022
    TOP STORY

    PD-L1 Interacts with Frizzled 6 to Activate β-Catenin and Form a Positive Feedback Loop to Promote Cancer Stem Cell Expansion

    Scientists discovered that programmed cell death ligand 1 (PD-L1) interacted with receptor Frizzled 6 to activate β-catenin signaling and increase β-catenin-targeted gene expression, such as a putative stem cell marker leucine-rich-repeat-containing G-protein-coupled receptor 5.
    [Oncogene]

    Abstract
    Resources for Your T Cell Therapy Research
    PUBLICATIONSRanked by the impact factor of the journal

    Exosomal circCARM1 from Spheroids Reprograms Cell Metabolism by Regulating PFKFB2 in Breast Cancer

    Researchers investigated breast cancer cell metabolism reprogramming by circular RNAs (circRNAs) from breast cancer stem cell (BCSC) exosomes and found that BCSC exosome-derived circCARM1 played an important role in breast cancer cell glycolysis.
    [Oncogene]

    Abstract

    Autophagy Inhibits Cancer Stemness in Triple-Negative Breast Cancer via miR-181a-Mediated Regulation of ATG5 and/or ATG2B

    The authors identified that autophagy flux was inhibited in triple-negative breast cancer (TNBC) stem cells. miRNA-181a (miR-181a) expression is upregulated both in TNBC CSCs and patient tissues.
    [Molecular Oncology]

    AbstractFull Article

    Stem-Like Breast Cancer Cells in the Activated State Resist Genetic Stress via TGFBI-ZEB1

    Investigators characterized a population of stem-like breast cancer cells expressing the integrin αvβ3 as transcriptionally related to activated stem/basal cells in the normal human mammary gland.
    [npj Breast Cancer]

    Full Article

    MUC1-C Dictates JUN and BAF-Mediated Chromatin Remodeling at Enhancer Signatures in Cancer Stem Cells

    The authors demonstrated that MUC1-C drives global changes in chromatin architecture in the dedifferentiation of castrate-resistant prostate cancer and triple-negative breast cancer cells.
    [Molecular Cancer Research]

    AbstractFull Article

    Sox9/CXCL5 Axis Facilitates Tumor Cell Growth and Invasion in Hepatocellular Carcinoma

    Investigators observed that the increase of Sox9 significantly promoted hepatocellular carcinoma cell growth and invasion in cell cultures, whereas knockdown of Sox9 showed the opposite effects, suggesting that Sox9 may regulate the proliferation and invasion of hepatoma cells in an autocrine manner.
    [FEBS Journal]

    Abstract

    FOXP3 Activated-LINC01232 Accelerates the Stemness of Non-Small Cell Lung Carcinoma by Activating TGF-β Signaling Pathway and Recruiting IGF2BP2 to Stabilize TGFBR1

    Flow cytometry and sphere formation assays indicated that LINC01232 significantly promoted non-small cell lung carcinoma cell stemness.
    [Experimental Cell Research]

    Abstract

    Notch Pathway Inhibition Mediated by Arsenic Trioxide Depletes Tumor Initiating Cells in Small Cell Lung Cancer

    Researchers demonstrated that As2O3 had a remarkable inhibitory effect on tumor initiating cells of small cell lung cancer both in vitro and in vivo, and the mechanism might have involved the down-regulation of Notch pathway.
    [Molecular Biology Reports]

    Abstract

    Long Non-Coding RNA TPT1-AS1 Suppresses APC Transcription in a STAT1-Dependent Manner to Increase the Stemness of Colorectal Cancer Stem Cells

    Stem cells from colorectal cancer HCT116 and CACO2 cells were isolated. TPT1-AS1 was significantly highly expressed in the CSCs compared to non-stem cells.
    [Molecular Biotechnology]

    Abstract
    Enjoy your weekend. Your cells will too. Reduce medium acidosis with mTeSR™ Plus.
    REVIEWS

    Programmed Cell Death 1 Ligand 1 Signals in Cancer Cells

    The authors discuss historical and recent advances in understanding cancer cell-intrinsic programmed death ligand 1 signals, mechanisms for signal controls and important immunopathologic consequences including resistance to cytotoxic agents, targeted small molecules and immunotherapies.
    [Nature Reviews Cancer]

    Abstract

    Emerging Roles of CD133 in the Treatment of Gastric Cancer, a Novel Stem Cell Biomarker and Beyond

    Scientists summarize the current knowledge of the role of CD133 expression in gastic cancer and identify promising new strategies for treatment and management of gastric cancer.
    [Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences]

    AbstractGraphical Abstract
    INDUSTRY AND POLICY NEWS

    IMV Announces First Patient Dosed in the VITALIZE Phase IIB Clinical Study Evaluating its Lead Compound, MVP-S, in Combination with KEYTRUDA® (Pembrolizumab) in Patients with r/r DLBCL

    IMV, Inc., a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, announced a first patient dosed in the VITALIZE Phase IIB clinical trial.
    [IMV Inc.]

    Press Release

    Evaxion Biotech Receives Regulatory Clearance to Initiate Phase II Trial of EVX-01 in Combination with KEYTRUDA® for Treatment of Melanoma

    Evaxion Biotech A/S announced it received clearance from the Australia Therapeutic Goods Administration to initiate a Phase IIb trial of its patient specific cancer immunotherapy EVX-01 in combination with Merck & Co., Inc.’s anti-PD-1 therapy KEYTRUDA®.
    [Evaxion Biotech A/S]

    Press Release
    FEATURED EVENT

    Lorne Cancer 2022

    February 10 – 12, 2022
    Lorne, Victoria, Australia

    > See All Events

    JOB OPPORTUNITIES

    PhD Student – Chronic Lymphocytic Leukemia

    Luxembourg Institute of Health – Luxembourg, Luxembourg

    Postdoctoral Research Fellow – Genetic Alterations in Prostate Cancer

    Wayne State University School of Medicine – Detroit, Michigan, United States

    Postdoctoral Research Associate – Drug Responses in Glioblastoma

    Queen Mary University of London – London, England, United Kingdom

    Postdoctoral Research Associate – Tumor Stem Cells

    Queen Mary University of London – London, England, United Kingdom

    Scientist – CART T Cell Cancer Immunotherapies

    Children’s Hospital of Philadelphia – Philadelphia, Pennsylvania, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cancer Stem Cell News Twitter